# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | Raffles Medical Group Ltd |
| Establishment Date | May 16, 1976 |
| Headquarters Location | Singapore, Singapore |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | The Group invests in technology and sustainable practices to minimize environmental impact, including implementing a bespoke Laboratory Information System to enhance efficiency and testing capacity. The Raffles Healthcare Institute provides a unified platform for training healthcare professionals across multiple disciplines, emphasizing clinical, operational, and service excellence. The Group also conducts cybersecurity tabletop exercises and maintains ISO 27001 certification for information security management, supported by ongoing employee education and external IT security services. | The Group leverages digital and telemedicine platforms such as RafflesConnect to enhance healthcare delivery and operational efficiency. It invests in advanced medical technologies, including a new Cardiology PACS platform for remote cardiac test reporting, and continuously develops its healthcare talent pipeline through the Raffles Healthcare Institute and partnerships with medical schools. The Group also implements robust IT security measures, achieving ISO 27001 certification and the Cyber Essentials Mark in 2023, and promotes continuous staff training in cybersecurity and clinical skills. |
| Product Advantages | The Group operates four hospitals and over 100 multi-disciplinary clinics across 14 cities in Asia, offering a broad range of medical services including family medicine, specialist care, diagnostics, health screening, and emergency services. It provides tailored healthcare packages through collaborations with insurance companies and corporations, and offers health insurance products via Raffles Health Insurance. The Group also launched new customer solutions such as critical illness coverage and reproductive health benefits, and expanded its presence with a second medical centre in Japan. | The Group offers a broad portfolio including healthcare services (medical clinics, pharmaceutical and nutraceutical products, diagnostic equipment), hospital services (specialised medical services, medical laboratory, imaging centres), insurance products via Raffles Health Insurance, and health and lifestyle products through Raffles Health. It expanded specialty services in hospitals and clinics, launched new insurance products such as the Raffles Cancer Guard Rider and a Digital Term Life product, and enhanced its supplement range focusing on maternity and paediatric segments. |
| Brand Recognition | The Group is recognized as a trusted healthcare partner with a 48-year history, operating in multiple countries across Asia. It maintains strong relationships with patients, employees, and communities, supported by professional governance committees overseeing clinical quality and patient safety. The Group’s hospital in Singapore received the American Nurses Credentialing Centre Nursing Continuing Professional Development Premier Award in 2024. It is a member of numerous professional associations in Singapore and China, reinforcing its commitment to quality, ethics, and professionalism. | The Group is recognized as a trusted healthcare provider with long-term relationships across 14 cities in Asia. It maintains a strong reputation for clinical quality and patient safety, supported by professional governance committees and adherence to rigorous standards. Raffles Hospital Singapore is the only hospital in Singapore accredited with Distinction by the American Nursing Credentialing Centre for nursing continuing professional development. The Group also received the 'Most Transparent Company Award' for Healthcare at the SIAS 2023 Investors Choice Award. |
| Reputation Ratings | The Group’s governance framework includes oversight of sustainability strategies and ESG targets by the Board and Audit & Risk Committee, which also reviews climate-related risks in alignment with ISSB and TCFD standards. It maintains certifications such as BizSAFE Level 3 for workplace safety and health, ISO 27001 for information security, and the Cyber Essentials mark by the Cyber Security Agency of Singapore. The Group enforces a zero-tolerance policy on corruption and bribery, mandates anti-corruption training for employees, and has a whistleblowing policy overseen by the Board. It reports on sustainability performance annually and engages stakeholders regularly to address ESG concerns. | The Group has attained ISO 27001 certification for its information security management system and was awarded the Cyber Essentials Mark by the Cyber Security Agency of Singapore in 2023. It complies with healthcare delivery regulations, labour standards, and ethical business practices across jurisdictions. The Group enforces a Supplier Code of Conduct to maintain ethical standards in its supply chain and has implemented comprehensive governance on sustainability, risk management, and ESG targets overseen by the Board and dedicated committees. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | to be 'The Trusted Partner for Health' , for all our patients, their families, corporations, communities, and governments. |
| Vision Statement | To Our Patients, Our Best |
| Core Values | compassion, commitment, excellence, team-based care, and value |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 751,564.0 | 706,920.0 | 822,916.0 | Thousands | SGD |
| Cost of Goods Sold | (61,180.0) | (57,922.0) | (61,112.0) | Thousands | SGD |
| Gross Profit | N/A | N/A | N/A | Thousands | SGD |
| Operating Expense | N/A | N/A | N/A | Thousands | SGD |
| Operating Income | 82,494.0 | 115,755.0 | N/A | Thousands | SGD |
| Net Profit | 62,282.0 | 91,090.0 | 143,400.0 | Thousands | SGD |
| Income before income taxes | 86,962.0 | 119,439.0 | 191,340.0 | Thousands | SGD |
| Income tax expense(benefit) | (24,680.0) | (28,349.0) | (47,940.0) | Thousands | SGD |
| Interest Expense | (5,779.0) | (6,078.0) | (6,882.0) | Thousands | SGD |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | 1,530,794.0 | 1,528,230.0 | 1,531,794.0 | Thousands | USD |
| Current Assets | 516,320.0 | 484,697.0 | 494,349.0 | Thousands | USD |
| Non-Current Assets | 1,014,474.0 | 1,043,533.0 | 1,037,445.0 | Thousands | USD |
| Total Liabilities | 465,815.0 | 484,378.0 | 504,044.0 | Thousands | USD |
| Current Liabilities | 381,937.0 | 379,384.0 | 362,990.0 | Thousands | USD |
| Non-Current Liabilities | 83,878.0 | 104,994.0 | 141,054.0 | Thousands | USD |
| Shareholders' Equity | 1,064,979.0 | 1,043,852.0 | 1,027,750.0 | Thousands | USD |
| Retained Earnings | 609,960.0 | 592,293.0 | 572,826.0 | Thousands | USD |
| Total Equity and Liabilities | 1,530,794.0 | 1,528,230.0 | 1,531,794.0 | Thousands | USD |
| Inventories | 10,762.0 | 12,465.0 | 13,098.0 | Thousands | USD |
| Prepaid Expenses | 3,390.0 | 2,658.0 | N/A | Thousands | USD |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | 86,254.0 | 189,312.0 | N/A | Thousands | USD |
| Net Cash Flow from Investing | (9,873.0) | (12,409.0) | N/A | Thousands | USD |
| Net Cash Flow from Financing | (76,203.0) | (85,523.0) | N/A | Thousands | USD |
| Net Increase/Decrease in Cash | 178.0 | 91,380.0 | N/A | Thousands | USD |
| Dividends | (44,576.0) | (70,683.0) | (70,473.0) | Thousands | USD |


## S2.4: Key Financial Metrics

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Gross Margin | 108.14% | 108.19% | 107.43% | Thousands | SGD |
| Operating Margin | 10.98% | 16.37% | N/A | Thousands | SGD |
| Net Profit Margin | 8.29% | 12.89% | 17.43% | Thousands | SGD |
| Current Ratio | 135.18% | 127.76% | 136.19% | Thousands | SGD |
| Quick Ratio | 131.48% | 123.77% | N/A | Thousands | SGD |
| Interest Coverage | 1427.48% | 1904.49% | N/A | Thousands | SGD |
| Asset Turnover | 49.14% | 46.20% | N/A | Thousands | SGD |
| Debt-to-Equity | 43.74% | 46.40% | 49.04% | Thousands | SGD |
| Return on Equity | 5.91% | 8.79% | N/A | Thousands | SGD |
| Return on Assets | 4.07% | 5.95% | N/A | Thousands | SGD |
| Effective Tax Rate | 28.38% | 23.74% | 25.05% | Thousands | SGD |
| Dividend Payout Ratio | 71.57% | 77.60% | 49.14% | Thousands | SGD |

## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | Healthcare services: $295,050, Hospital services: $345,652, Insurance services: $178,000, Investment holdings: $44,894 | Healthcare services: $283,427, Hospital services: $330,589, Insurance services: $144,453, Investment holdings: $45,223 | Healthcare services: $316,277, Hospital services: $445,036, Insurance services: $139,681, Investment holdings: $45,886 |
| Revenue by Geographic Region | Singapore: $669,145, Greater China: $65,302, Rest of Asia: $17,117 | Singapore: $631,108, Greater China: $59,324, Rest of Asia: $16,488 | Singapore: $756,131, Greater China: $50,247, Rest of Asia: $16,538 |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | Revenue decreased from $822,916 in 2022 to $706,920 in 2023, and further declined to $751,564 in 2024, indicating a downward trend in overall revenue. The gross margin remained relatively stable, with a slight increase from 107.43% in 2022 to 108.19% in 2023, and a marginal decrease to 108.14% in 2024. Revenue by product shows a decline in Healthcare services from $316,277 in 2022 to $295,050 in 2024, and Hospital services from $445,036 in 2022 to $345,652 in 2024, while Insurance services increased from $139,681 in 2022 to $178,000 in 2024. Geographic revenue distribution shows a significant drop in Singapore from $756,131 in 2022 to $669,145 in 2024, while Greater China and Rest of Asia saw modest increases. |
| Operating Efficiency | Operating margin decreased from 16.37% in 2023 to 10.98% in 2024, indicating a decline in operating efficiency. Operating income fell from $115,755 in 2023 to $82,494 in 2024, reflecting a decrease in profitability relative to revenue. The relationship between operating income and revenue shows a concerning trend, as the operating income is significantly lower in 2024 compared to the previous year, suggesting potential issues in cost management and operational performance. |
| External & One-Off Impact | The effective tax rate increased from 23.74% in 2023 to 28.38% in 2024, which negatively impacted net profit, contributing to a decline from $91,090 in 2023 to $62,282 in 2024. There are no specific non-recurring items mentioned, but the overall decline in net profit suggests external factors may be affecting profitability, including potential market challenges or increased competition. |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | In 2024, the company's total assets slightly increased to SGD 1,530,794, while total liabilities decreased to SGD 465,815, indicating improved balance sheet strength. The equity position strengthened with shareholders' equity rising to SGD 1,064,979. Current assets increased to SGD 516,320, enhancing liquidity, while the current ratio improved to 135.18%, indicating a solid capital structure. | In 2023, total assets were SGD 1,528,230, with total liabilities at SGD 484,378. The shareholders' equity was SGD 1,043,852, reflecting a stable financial position. Current assets were SGD 484,697, and the current ratio was 127.76%, suggesting adequate liquidity and a manageable capital structure. |
| Profitability and earnings quality | The revenue for 2024 reached SGD 751,564, showing growth from 2023's SGD 706,920. However, net profit decreased to SGD 62,282, resulting in a net profit margin of 8.29%, down from 12.89% in 2023. The return on equity (ROE) fell to 5.91%, indicating a decline in earnings quality and sustainability compared to 8.79% in 2023. | In 2023, the company reported revenue of SGD 706,920 and a net profit of SGD 91,090, yielding a net profit margin of 12.89%. The ROE was 8.79%, reflecting strong profitability and earnings quality, although it was lower than the previous year's performance. |
| Operational efficiency | The operating income for 2024 was SGD 82,494, with an operating margin of 10.98%, a decline from 16.37% in 2023. The asset turnover ratio improved to 49.14%, indicating better asset utilization. However, net cash from operations dropped significantly to SGD 86,254, highlighting potential challenges in operational efficiency and working capital management. | In 2023, the operating income was SGD 115,755, with an operating margin of 16.37%. The asset turnover ratio was 46.20%, suggesting effective asset utilization. Net cash from operations was robust at SGD 189,312, indicating strong operational efficiency and effective working capital management. |
| Financial risk identification and early warning | In 2024, the debt to equity ratio improved to 43.74%, indicating better debt management. The interest coverage ratio remained high at 1427.48%, suggesting low financial risk. However, the effective tax rate increased to 28.38%, which could impact future profitability. Liquidity ratios remained strong, with a current ratio of 135.18%. | The debt to equity ratio in 2023 was 46.40%, reflecting a moderate level of financial risk. The interest coverage ratio was 1904.49%, indicating strong ability to cover interest expenses. The effective tax rate was lower at 23.74%, which positively impacted net income. The current ratio was 127.76%, suggesting adequate liquidity. |
| Future financial performance projection | Based on 2024 data, the company is expected to focus on improving profitability and operational efficiency. The decline in net profit margin and operating margin suggests a need for cost management strategies. Investment activities are projected to remain cautious, with a focus on maintaining cash flow sustainability and potentially revising the dividend policy due to lower net cash from operations. | In 2023, the company showed strong revenue growth and profitability, indicating a positive outlook for future performance. The focus on market expansion, particularly in Singapore and Greater China, along with effective cash flow management, suggests potential for continued growth. The dividend policy was sustainable, reflecting confidence in future earnings. |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | The company primarily operates in the healthcare sector, generating revenue through multiple streams including the provision of medical services, insurance products, and rental income from investment properties. Revenue from medical services is recognized when the services are rendered, while insurance revenue is recognized over the premium period. The investment holdings segment generates revenue from leasing investment properties to external parties, with rental income recognized on a straight-line basis over the lease term. | The company operates through four reportable segments: Healthcare services, Hospital services, Investment holdings, and Insurance services. It generates revenue primarily from the provision of medical services, inpatient services, and trading in pharmaceutical and nutraceutical products. Revenue is recognized when services are rendered or goods are delivered. The healthcare services segment also includes management and consultancy services, while the investment holdings segment generates revenue from leasing investment properties. |
| Market Position | The company holds a significant market position in the healthcare industry, with a strong presence in Singapore and expanding operations in Greater China, Vietnam, Cambodia, and Japan. It is recognized as a market leader in Singapore, with a revenue of S$751.6 million in 2024, reflecting a growth of 6.3% from the previous year. The Hospital Services Division generated S$345.7 million, while the Healthcare Services Division and Raffles Health Insurance grew by 4.1% and 23.2%, respectively. The company faces keen competition but aims to strengthen its competitive edge through strategic expansions and enhanced service offerings. | The company is a market leader in Singapore's healthcare sector, with a strong brand presence and a network of over 100 multi-disciplinary clinics across 14 cities in Asia. In 2023, the core Hospital Services division registered revenue growth of 4.5% and profit growth of 52.2%. The healthcare services division saw a decline in revenue due to lower demand post-COVID-19. The insurance arm, Raffles Health Insurance, grew its revenue by 25.6% to S$144.5 million, indicating a competitive position in the health insurance market. |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | The Group faces market risks from changes in market prices, including foreign exchange rates, interest rates, and competition from both established players and new entrants in the healthcare industry. To mitigate these risks, the Group aims to manage and control market risk exposures within acceptable parameters while optimizing returns. | The Group faces market risks from changes in market prices, including foreign exchange rates, interest rates, and equity prices, which could affect income and the value of financial instruments. The Group aims to manage these risks within acceptable parameters while optimizing returns. |
| Operational Risks | Operational risks include potential business disruptions due to external factors beyond the Group's control, as well as challenges related to maintaining high standards in healthcare delivery. The Group conducts annual Business Continuity Planning exercises to enhance operational preparedness and resilience against such disruptions. | Operational risks include disruptions from external factors, such as pandemics, which previously led to the shutdown of non-essential services. The Group has enhanced its operational resilience and business continuity plans to adapt to such challenges and ensure ongoing service delivery. |
| Financial Risks | The Group is exposed to various financial risks, including credit, liquidity, foreign currency, and interest rate risks. To manage these risks, the Group actively monitors its financial position and implements robust risk management policies, including maintaining adequate liquidity and stress-testing its financial stability under various scenarios. | The Group is exposed to financial risks including credit, liquidity, foreign currency, and interest rate risks. It actively monitors these risks and has implemented policies to manage them effectively, including maintaining adequate liquidity and monitoring financial instruments. |
| Compliance Risks | The Group operates in a highly regulated environment, requiring compliance with various laws and regulations. To minimize non-compliance risks, the Group closely monitors regulatory developments and engages with authorities to ensure adherence to relevant standards, while also conducting regular audits to evaluate compliance effectiveness. | The Group operates in a highly regulated environment, requiring compliance with various licensing and governmental approvals. To mitigate non-compliance risks, the Group closely monitors regulatory developments and engages with authorities to ensure adherence to changing regulations. |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| Dr Loo Choon Yong | Executive Chairman and Non-Independent Director | £7,333,190,000 |
| Mr Tan Soo Nan | Executive and Non-Independent Director | £516,579,000 |
| Dr Sarah Lu Qinghui | Executive and Non-Independent Director | £413,893,000 |
| Mr Eric Ang Teik Lim | Non-Executive and Independent Director | £73,515,000 |
| Mr Lew Yoong Keong Allen | Non-Executive and Independent Director | £163,261,000 |
| Mr Png Cheong Boon | Non-Executive and Independent Director | £80,000,000 |
| Mr Tan Wern Yuen | Non-Executive and Independent Director | £107,491,000 |
| Ms Chong Chuan Neo | Non-Executive and Independent Director | £107,491,000 |
| Professor Sung Jao Yiu | Non-Executive and Independent Director | £107,491,000 |
| Mr Lim Sim Seng | Non-Executive and Independent Director | £65,597,000 |
| Mr Olivier Lim Tse Ghow | Non-Executive and Non-Independent Director | £90,400,000 |
| Dr Lu Liangjian David | Non-Executive and Non-Independent Director | N/A |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | The Group's ERM framework provides a systematic process for identifying and reviewing the nature and complexity of risks involved in each Business and/or Operating Unit. The Board oversees the risk management process, ensuring that risk awareness is embedded in day-to-day operations. The risk assessment includes identifying key risk areas such as financial, operational, compliance, information technology, and climate-related risks, based on feedback from internal and external auditors. | The Group has adopted an entity-wide risk assessment framework to enhance its risk management capabilities. This framework provides a holistic overview of the Group's risk profile by identifying key risks, control measures, risk tolerance, risk ownership, and assurance on residual risk. The framework is reviewed by the Audit & Risk Committee (ARC) and approved by the Board annually. The Group conducts regular Enterprise Risk Assessment exercises at least once a year to keep up to date on its risks. |
| Control activities | The Group has implemented various control measures, including robust underwriting guidelines for insurance risks, compliance with internal IT and security policies, and a whistleblowing policy to protect against misconduct. The Group also conducts regular training on anti-bribery and anti-corruption, and has a Block Leave Policy for employees in key functions to ensure checks and balances. | The Group has established risk management policies to identify and analyze risks, set appropriate risk limits and controls, and monitor risks and adherence to limits. Specific control measures include a Code of Business Conduct, training on data security, anti-bribery, and anti-corruption, as well as a whistleblowing policy. The Group also has a Block Leave Policy for employees in key functions to ensure checks and balances. |
| Monitoring mechanisms | The Audit & Risk Committee (ARC) oversees the internal audit function, which operates independently and reports directly to the ARC. The ARC reviews internal audit reports and monitors Management's responsiveness to findings. The Management Risk Committee (MRC) also plays a role in monitoring risk management and internal controls across the organization. | The Audit & Risk Committee (ARC) oversees the Group's risk management and internal controls, reviewing the adequacy and effectiveness of these systems annually. Internal Audit provides independent assurance on the adequacy and effectiveness of the Group's risk management and internal controls, reporting directly to the ARC. The Management Risk Committee (MRC) also reviews and monitors compliance with risk management policies. |
| Identified material weaknesses or deficiencies | In FY2024, the ARC reviewed internal audit reports that highlighted any material non-compliance or lapses in internal controls, along with recommendations for improvement. Major control weaknesses in financial reporting identified during the statutory audit were also presented to the ARC. | N/A |
| Effectiveness | The Board, with the concurrence of the ARC, believes that the Group has adequate and effective risk management systems and internal controls in place to mitigate critical and significant risks. The internal audit function is considered effective, adequately resourced, and independent, with the ARC satisfied that the Group's internal control and risk management systems are adequate and effective. | The Board, with the concurrence of the ARC, is of the opinion that the Group has adequate and effective risk management systems and internal controls in place to mitigate critical and significant risks. The ARC is satisfied that the internal audit function is effective, adequately resourced, and independent, and that the Group's internal control and risk management systems are adequate and effective. |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | {'description': 'On 18 January 2024, RJC Ltd, a subsidiary of the Company, completed the acquisition of the remaining 49% which it does not already hold, in the equity interest of RSM Ltd, Japan (RSM). On completion of this acquisition, RSM becomes a wholly owned subsidiary of RJC Ltd. The consideration paid to NCI was $367,000. Additionally, on 25 April 2024, the Group acquired an additional 7.5% equity interest in Raffles Japanese Clinic Pte Ltd (RJC), increasing its ownership from 80% to 87.5%. The consideration paid for this acquisition was $1,197,000.'} | In 2023, RJC Ltd, a subsidiary of the Company, completed the acquisition of the remaining 49% equity interest in RSM Ltd, Japan, for a total cash consideration of JPY40,089,000 ($367,000). This acquisition allows RSM Ltd to become a wholly owned subsidiary of RJC Ltd, enhancing the Group's operational capabilities in Japan. |
| New technologies | {'description': 'In 2024, Raffles Hospital enhanced its laboratory capabilities through the implementation of laboratory automation and a new bespoke IT system, which is expected to deliver increased efficiency and testing capacity. Furthermore, Raffles Dental introduced advanced 3D intraoral scanning technology to optimize workflows and improve treatment outcomes. The Group also invested in upgrading its IT systems to enhance cybersecurity and data protection, obtaining ISO 27001 certification for its information security management system.'} | The Group has introduced a new agent portal for Raffles Health Insurance to improve customer experience and operational efficiency. Additionally, Raffles Heart Centre expanded its angiography suite and commissioned a new Cardiac Catheterisation Laboratory, investing in a new Cardiology PACS platform for remote viewing and reporting of cardiac tests. The Group is also promoting new technologies such as telemedicine to adapt to healthcare-related challenges. |
| Organisational Restructuring | {'description': 'The Group is committed to talent management and development, offering placements for undergraduate and advanced specialty trainees through partnerships with educational institutions. In 2024, the Group sponsored four employees for advanced diplomas, one for a degree program, and two for executive leadership programs. The employee turnover rate was reduced to 22% from 26% in 2023, indicating improved retention strategies. The Group also conducted a comprehensive refresh of hospital facilities to better serve patients, which will continue into 2025.'} | The Group is focused on talent management and workforce development, implementing various training programs such as the 'Driving Service Excellence' course for supervisors and managers. The Group has also developed a pipeline for healthcare talent to address shortages exacerbated by COVID-19, and it offers continuous education programs for nurses to maintain high standards of care. Furthermore, the Group is conducting compensation and benefits benchmarking to align with market practices. |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | The Group faces economic challenges including rising costs of energy and water, which are anticipated to continue increasing, impacting operational expenses and sustainability efforts. Additionally, the Group is exposed to financial risks such as credit, liquidity, foreign currency, and interest rate risks due to its regional presence, which could affect overall business performance. | The slower economic growth in Singapore, China, and other ASEAN countries is a concern, compounded by growing trade barriers and various geopolitical tensions. These factors may dampen demand for high-end healthcare services, necessitating a cautious approach to investment and operations. Additionally, the expectation of rising prices for energy and water presents a common challenge for all businesses, impacting operational costs and profitability. |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | The Group experiences keen competition from both established players and new entrants in the healthcare industry. The consolidation of smaller practices creates new competitors that challenge the Group's market position. As the Group expands beyond Singapore, it must develop expertise to navigate diverse regulatory and cultural environments while enhancing its organizational capabilities to maintain a competitive edge. | The Group faces keen competition from both established players and new entrants in the healthcare industry. The consolidation of smaller practices can create new competitors of significant size and scale, challenging the Group's market position. As the Group expands beyond Singapore, it must develop expertise to navigate different regulatory and cultural environments, while continuously enhancing its organizational capabilities to address diverse market challenges. |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | N/A | N/A |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | In 2024, Raffles Medical Group launched several new products and services, including Raffles Critical Illness for the Personal Lines market and the Raffles Women's Reproductive Health benefit for the Group Employee Benefits market. Additionally, Raffles Health developed and launched an oral skincare supplement, backed by clinical research, designed to combat skin aging and provide protection against sun damage. These initiatives reflect the company's commitment to continuously introducing differentiated products that cater to evolving customer needs. | In FY2023, Raffles Health Insurance launched new products designed to provide additional cancer coverage, including the Raffles Cancer Guard Rider, which offers protection for patients using treatments not included in the MOH's Cancer Drug List. This product features market-leading attributes such as traditional Chinese medicine and psychiatric counselling to support cancer patients during their recovery. Additionally, RHI introduced its first Digital Term Life product, available exclusively through a digital portal, enhancing customer experience and accessibility. |
